SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co.
MTC 2.730-2.5%1:39 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dan Spillane who wrote (1043)2/1/1999 8:37:00 PM
From: Anthony Wong  Read Replies (2) of 2539
 
(Dow Jones) Monsanto's Celebrex Soars To 55,000 Prescriptions In 2nd Wk

By Thomas M. Burton

CHICAGO (Dow Jones)--Sales of the new Monsanto Co. (MTC) arthritis-pain drug
Celebrex continued to soar in its second week on the market, according to
prescription-tracking information.

The drug, made by Monsanto's Searle pharmaceutical division and co-marketed by
Pfizer Inc. (PFE), generated 55,000 prescriptions for the two weeks ending Sunday,
Jan. 31.

That number far exceeded the slightly fewer than 12,000 prescriptions recorded by
Warner-Lambert Co.'s (WLA) cholesterol-lowering Lipitor in its first two weeks of
marketing in 1997. Lipitor now is a multibillion-dollar drug, and until Celebrex was No.
2 in generating the highest early sales results.

Pfizer's Viagra for impotence still holds the sales record for the first two weeks of
marketing, but Viagra sales slowed after several months amid safety concerns.

"Celebrex is really becoming a phenomenon," said drug-industry analyst Hemant K.
Shah. The prescription sales data were provided to Dow Jones by NDC Health
Information Services, a leading provider of health-care information that is able to track
prescription sales on a daily basis.

Shah said Celebrex had seized 6% of the arthritis-pain prescription drug market by late
last week, an unusually dramatic inroad after just two weeks on the market. That
success is especially impressive given that several of the leading pain-killers are
inexpensive generics, like ibuprofen and naproxen.


Celebrex is an especially important drug for Monsanto, which has borrowed heavily to
finance its ventures into agriculture-biotechnology and thus needs the income stream
from a blockbuster drug. The package-label wording granted to Monsanto by the Food
and Drug Administration had been viewed as limiting sales of the drug. But now, Shah
and other analysts are saying that Celebrex could very well exceed $1 billion in sales
during its first year on the market, which would be an unusual success.

Celebrex sales during the week ended Jan. 24 were approximately 10,000
prescriptions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext